MP41-07 UTILIZATION OF ExoDx PROSTATE TEST FOR PROSTATE CANCER RISK STRATIFICATION IN THE AFRICAN AMERICAN POPULATION

You have accessJournal of UrologyProstate Cancer: Markers I (MP41)1 May 2024MP41-07 UTILIZATION OF ExoDx PROSTATE TEST FOR PROSTATE CANCER RISK STRATIFICATION IN THE AFRICAN AMERICAN POPULATION Ronald F. Tutrone, Sonia Kumar, Christian Ray, Jason Alter, Grannum Sant, Yiyuan Yao, Vinita Verma, and Johan Skog Ronald F. TutroneRonald F. Tutrone , Sonia KumarSonia Kumar , Christian RayChristian Ray , Jason AlterJason Alter , Grannum SantGrannum Sant , Yiyuan YaoYiyuan Yao , Vinita VermaVinita Verma , and Johan SkogJohan Skog View All Author Informationhttps://doi.org/10.1097/01.JU.0001008896.93851.5b.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prostate cancer (PCa) affects men of all races but is particularly concerning among African American (AA) men. AA men are not only more likely to be diagnosed with prostate cancer but also tend to have more aggressive forms of the disease at every stage from prevention and screening to clinical outcomes, which calls for a focused approach to early detection and effective treatment options.1 The ExoDx Prostate (EPI) Test is a non-invasive urine test for assessing risk of high-grade prostate cancer (HGPCa) currently used in shared decision-making for men considering diagnostic prostate biopsy. METHODS: A large level 1 evidence clinical trial2 conducted in 2017 (Prostate Biopsy Decision Impact Trial) enrolled 1094 subjects considered for initial biopsy to either receive an EPI test result as part of their biopsy decision process, or to proceed with standard of care (SOC). This real-world study demonstrated the EPI test improved quality of care by improving compliance and more appropriately deferring low-risk men from having a prostate biopsy or referring higher-risk men to biopsy.2 After 2.5 years, 833/1094 subject records were assessed for outcomes based on the pre-biopsy EPI score in the ongoing 5-year follow-up of the Trial. RESULTS: AA men in the EPI arm and SOC arm were 21.7% (89/411) and 23% (97/422) respectively. This was consistent with the original utility study. For AA men, 41.6% (37/89) were diagnosed with HGPCa in the EPI arm compared to 29.9% (29/97) in the SOC arm. Over the 2.5 years follow-up period, significantly more HGPCa was detected in the EPI arm as compared to the SOC control arm. EPI had an impact on the decision to biopsy in the EPI arm. More subjects in the high-risk group in the EPI arm had a biopsy than in the SOC arm hence more HGPCa was detected in the EPI arm. CONCLUSIONS: In the 2.5-year follow-up study, many AA men in the SOC control cohort remained undiagnosed. This raises concerns about the potential for these individuals to be missed in the clinic. This data emphasizes the importance of utilizing the EPI test for risk assessment of high-risk prostate cancer in AA men. Using this test before a biopsy decision enables clinicians to enhance clinical outcomes and effectively manage patients' health. The ability to suggest men more likely to comply with Bx decisions and missing less HGPCa enhances quality of care for men. Download PPT Source of Funding: Exosome Diagnostics, Inc © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e675 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Ronald F. Tutrone More articles by this author Sonia Kumar More articles by this author Christian Ray More articles by this author Jason Alter More articles by this author Grannum Sant More articles by this author Yiyuan Yao More articles by this author Vinita Verma More articles by this author Johan Skog More articles by this author Expand All Advertisement PDF downloadLoading ...